Millions of data points from four unique research initiatives

Millions of data points from four unique research initiatives

RISK: Pediatric Risk Stratification Study

The RISK Study* is comprised of the largest well-characterized group of pediatric patients in the history of Crohn’s disease research. More than 1,800 patients, ages 6 to 17, were recruited at disease onset, and 913 are being prospectively followed for complications and response to therapies. Researchers at 28 clinics – 25 in the U.S. and three in Canada – collected biological samples, in addition to clinical, demographic, immunological, and genetic data.

During 2016, RISK investigators announced new discoveries from the study, developing a validated model to assess an individual child’s risk for Crohn’s disease complications within three to five years of diagnosis. In addition, researchers revealed new information about the effectiveness of early treatment with anti-tumor necrosis alpha (anti-TNF-a) antibody for children at risk of severe Crohn’s disease. These findings advance a potential approach to precision medicine.  The findings were published in March 2017 in the journal The Lancet.

Data / biosamples can be used in:

  • Drug targets and biomarkers discovery
  • Characterization of changes in microbiome, transcriptomics
  • Hypothesis / evidence generation
  • Comparative effectiveness research

This seminal work and its discovery represent a $10 million investment by the Crohn’s & Colitis Foundation, and nearly 10 years of work and collaborative science. Drs. Subra Kugathasan and Lee Denson share lead authorship with Dr. Thomas Walters from the Hospital for Sick Kids, Canada. In addition, Dr. Gregory Gibson (Institute of Technology, Georgia), Dr. Jeffrey Hyams (Connecticut Children’s Medical Center), and Dr. Marla Dubinsky (Mount Sinai Hospital, New York) share the senior and last authorships.

*Risk Stratification and Identification of Immunogenetic and Microbial Markers of Rapid Disease Progression in Children with Crohn’s Disease

For more information, contact Andres Hurtado-Lorenzo.